A new class of migraine medications, known as gepants, is set to launch in Germany, providing potential relief for the eight million migraine sufferers in the country. Unlike existing treatments, gepants can be used by patients with cardiovascular diseases and…
This year has seen remarkable advancements in healthcare and medicine, including breakthroughs in neurology, cancer treatment, and robotic surgery. Key studies unveiled new methods to combat Alzheimer’s and Parkinson’s diseases using genetically modified parasites, while researchers identified the HNF4A gene…
The American Academy of Neurology highlights twelve protective factors for brain health that individuals should discuss with their neurologists in the new year. These factors encompass sleep, mental health, nutrition, exercise, social support, injury prevention, blood pressure management, and more….
The European Union has approved Lecanemab, a groundbreaking drug developed by Biogen to slow down the progression of Alzheimer’s disease. Manufactured in Luterbach, Switzerland, it targets harmful amyloid proteins in the brain, improving cognitive function in early-stage patients. Despite some…
The European Medicines Agency (EMA) has recommended the approval of Lecanemab, an antibody that may slow the progression of Alzheimer’s disease, specifically for patients with light cognitive impairment and minimal risk factors. This marks the first EU endorsement targeting the…
